MacLeod S M, Sellers E M
Drugs. 1976;11(6):461-70. doi: 10.2165/00003495-197611060-00006.
Many drugs alter the anticoagulant effect of oral coumarins. It is essential that physicians be aware of interactions leading to increased or decreased anticoagulation or to erratic control. Interacting drugs can be classified as influencing the pharmacodynamics (pharmacological actions) or the pharmacokinetics (absorption, biotransformation, binding to plasma proteins, excretion) of oral coumarin anticoagulants. Significant pharmacodynamic interactions include those with vitamin K, salicylates, oestrogens, anabolic steroids, phenylbutazone and other anticoagulants. Significant pharmacokinetic interactions include those with cholestyramine, barbiturates, phenylbutazone, rifampicin and chloramphenicol. When prescribing coumarins, the physician should be fully aware of a patient's other drug therapy and the patient should be cautioned against adding new drugs without consultation. If changes in drug therapy are necessary, close monitoring of prothrombin time after the change is essential.
许多药物会改变口服香豆素的抗凝作用。医生必须了解那些导致抗凝作用增强或减弱或控制不稳定的相互作用。相互作用的药物可分为影响口服香豆素抗凝剂的药效学(药理作用)或药代动力学(吸收、生物转化、与血浆蛋白结合、排泄)两类。重要的药效学相互作用包括与维生素K、水杨酸盐、雌激素、同化类固醇、保泰松及其他抗凝剂的相互作用。重要的药代动力学相互作用包括与考来烯胺、巴比妥类、保泰松、利福平及氯霉素的相互作用。在开具香豆素类药物处方时,医生应充分了解患者的其他药物治疗情况,并且应告诫患者未经咨询不要自行添加新药。如果有必要改变药物治疗,改变后密切监测凝血酶原时间至关重要。